DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Lymphocytic Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Small Lymphocytic Lymphoma Pipeline Report to explore emerging therapies, key Small Lymphocytic Lymphoma Companies, and future Small Lymphocytic Lymphoma treatment landscapes @ Small Lymphocytic Lymphoma Pipeline Outlook Report

Key Takeaways from the Small Lymphocytic Lymphoma Pipeline Report

• In May 2025, Merck Sharp & Dohme LLC announced a study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
• In May 2025, AbbVie announced a phase 2 study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2).
• In May 2025, BeiGene announced a study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
• DelveInsight’s Small Lymphocytic Lymphoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Small Lymphocytic Lymphoma treatment.
• The leading Small Lymphocytic Lymphoma Companies such as Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others.
• Promising Small Lymphocytic Lymphoma Therapies such as ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.

Discover how the Small Lymphocytic Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth Small Lymphocytic Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Small Lymphocytic Lymphoma Clinical Trials and Studies

Small Lymphocytic Lymphoma Emerging Drugs Profile

• TQ-B3525: Chia Tai Tianqing Pharmaceutical Group

TQ-B3525 is a novel and selective oral PI3K α/δ inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K α and PI3K δ in pre-clinical research. TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients.Currently,the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

• LOXO-305: Loxo Oncology

Pirtobrutinib (LOXO-305), is an investigational, oral, highly-selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and marginal zone lymphoma. Currently available BTK inhibitors irreversibly inhibit BTK and the long-term efficacy of these therapies can be limited by acquired resistance. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. Pirtobrutinib is currently being studied in multiple clinical trials. Safety and efficacy have not been established for the uses being studied.

• IOV 2001: Iovance Biotherapeutics

IOV 2001 is an adoptive cell therapy consist of autologous peripheral blood lymphocytes (PBL) being developed by Iovance Biotherapeutics. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

The Small Lymphocytic Lymphoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Small Lymphocytic Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Lymphocytic Lymphoma Treatment.
• Small Lymphocytic Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Small Lymphocytic Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Lymphocytic Lymphoma market.

Get a detailed analysis of the latest innovations in the Small Lymphocytic Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Small Lymphocytic Lymphoma Unmet Needs

Small Lymphocytic Lymphoma Companies

Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics and others.

Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Small Lymphocytic Lymphoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming Small Lymphocytic Lymphoma Therapies and key Small Lymphocytic Lymphoma Developments @ Small Lymphocytic Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Small Lymphocytic Lymphoma Pipeline Report

• Coverage- Global
• Small Lymphocytic Lymphoma Companies- Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics and others.
• Small Lymphocytic Lymphoma Therapies- ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.
• Small Lymphocytic Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Small Lymphocytic Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Small Lymphocytic Lymphoma drug development? Find out in DelveInsight’s exclusive Small Lymphocytic Lymphoma Pipeline Report—access it now! @ Small Lymphocytic Lymphoma Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Small Lymphocytic Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Small Lymphocytic Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. LOXO-305: Loxo Oncology
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase I/II)
14. TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Small Lymphocytic Lymphoma Key Companies
21. Small Lymphocytic Lymphoma Key Products
22. Small Lymphocytic Lymphoma – Unmet Needs
23. Small Lymphocytic Lymphoma – Market Drivers and Barriers
24. Small Lymphocytic Lymphoma – Future Perspectives and Conclusion
25. Small Lymphocytic Lymphoma Analyst Views
26. Small Lymphocytic Lymphoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/small-lymphocytic-lymphoma-pipeline-insight